Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2014 /
New immunotherapy compound effective, safe in ALL patients with minimal residual disease

6th - 9th Dec 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.12.14
Views: 2606

Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany

At a press conference at ASH 2014, Dr Gökbuget presents the findings of a study which pairs new and evolving methods to detect minimal residual disease (MRD) with a new antibody that recruits T cells to attack lingering disease cells in acute lymphocytic leukaemia (ALL).

Read the news story and watch the interview for more.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation